{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:45:14Z","timestamp":1789159514374,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>MTOR inhibition is an effective treatment for many manifestations of tuberous sclerosis complex. Because mTOR inhibition is a disease modifying therapy, lifelong use will most likely be necessary. This study addresses the long-term effects of mTOR inhibitors on lipid and glucose metabolism and aims to provide better insight in the incidence and time course of these metabolic adverse effects in treated TSC patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients who gave informed consent for the nationwide TSC Registry and were ever treated with mTOR inhibitors (sirolimus and\/or everolimus) were included. Lipid profiles, HbA1c and medication were analysed in all patients before and during mTOR inhibitor treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 141 patients, the median age was 36\u00a0years, median use of mTOR inhibitors 5.1\u00a0years (aimed serum levels 3.0\u20135.0\u00a0\u00b5g\/l). Total cholesterol, LDL- and HDL-cholesterol levels at baseline were similar to healthy reference data. After start of mTOR inhibition therapy, total cholesterol, LDL-cholesterol and triglycerides increased significantly and were higher compared to healthy reference population. Mean total cholesterol levels increased by 1.0\u00a0mmol\/L after 3\u20136\u00a0months of mTOR inhibition therapy but did not increase further during follow-up. In this study, 2.5% (3\/118) of patients developed diabetes (defined as an HbA1c\u2009\u2265\u200948\u00a0mmol\/mol) during a median follow-up of 5\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Hypercholesterolemia is a frequent side effect of mTOR inhibition in TSC patients, and predominantly occurs within the first year of treatment. Although hyperglycemia is a frequent side effect in other indications for mTOR inhibition, incidence of diabetes mellitus in TSC patients was only 2.5%. This may reflect the difference of mTOR inhibition in patients with normal mTOR complex pathway function versus patients with overactive mTOR complex signaling due to a genetic defect (TSC patients).\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02385-8","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:03:06Z","timestamp":1657278186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-6948","authenticated-orcid":false,"given":"Femke V. M.","family":"Mulder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien F. H. I.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Westerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fried J. T.","family":"Zwartkruis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendela L.","family":"de Ranitz-Greven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"issue":"4","key":"2385_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000254569","volume":"33","author":"CH Hong","year":"2009","unstructured":"Hong CH, Darling TN, Lee CH. Prevalence of tuberous sclerosis complex in Taiwan: A National Population-Based Study. Neuroepidemiology. 2009;33(4):335\u201341.","journal-title":"Neuroepidemiology"},{"issue":"19","key":"2385_CR2","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801\u201311.","journal-title":"N Engl J Med"},{"issue":"8","key":"2385_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS ONE. 2017;12(8): e0180939.","journal-title":"PLoS ONE"},{"issue":"6","key":"2385_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS ONE. 2016;11(6): e0158476.","journal-title":"PLoS ONE"},{"issue":"6","key":"2385_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24523","volume":"78","author":"DN Franz","year":"2015","unstructured":"Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929\u201338.","journal-title":"Ann Neurol"},{"issue":"10056","key":"2385_CR6","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"issue":"6","key":"2385_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","volume":"17","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596\u2013603.","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"2385_CR8","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/EJE-13-0586","volume":"170","author":"B Verg\u00e8s","year":"2014","unstructured":"Verg\u00e8s B, Walter T, Cariou B. Ndocrine side effects of anti-cancer drugs: Effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol. 2014;170(2):R43-55.","journal-title":"Eur J Endocrinol"},{"issue":"9637","key":"2385_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"7","key":"2385_CR10","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","volume":"8","author":"BL Kasiske","year":"2008","unstructured":"Kasiske BL, De Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008;8(7):1384\u201392.","journal-title":"Am J Transplant"},{"issue":"4","key":"2385_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","volume":"26","author":"J Trelinska","year":"2015","unstructured":"Trelinska J, Dachowska I, Kotulska K, Fendler W, Jozwiak S, Mlynarski W. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs. 2015;26(4):437\u201342.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2385_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ajmg.c.31655","volume":"178","author":"DN Franz","year":"2018","unstructured":"Franz DN, Krueger DA. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):365\u201373.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"2385_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, Roberds S, Smith K, Sampson J, Korf B, et al. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"12","key":"2385_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/088307389801301206","volume":"13","author":"ES Roach","year":"1998","unstructured":"Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13(12):624\u20138.","journal-title":"J Child Neurol"},{"key":"2385_CR15","unstructured":"NCI, NIH, DHHS. Common Terminology Criteria for Adverse Events v4.0. NIH Publ [Internet]. 2009;0\u201371. Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"2385_CR16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Supplement 1):S13\u201328.","DOI":"10.2337\/dc19-S002"},{"issue":"5","key":"2385_CR17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jacl.2018.05.011","volume":"12","author":"JW Balder","year":"2018","unstructured":"Balder JW, Lansberg PJ, Hof MH, Wiegman A, Hutten BA, Kuivenhoven JA. Pediatric lipid reference values in the general population: the Dutch lifelines cohort study. J Clin Lipidol. 2018;12(5):1208\u201316.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2385_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jacl.2017.05.007","volume":"11","author":"JW Balder","year":"2017","unstructured":"Balder JW, de Vries JK, Nolte IM, Lansberg PJ, Kuivenhoven JA, Kamphuisen PW. Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: age- and gender-specific baseline lipid values and percentiles. J Clin Lipidol. 2017;11(4):1055-1064.e6.","journal-title":"J Clin Lipidol"},{"key":"2385_CR19","doi-asserted-by":"publisher","first-page":"35392","DOI":"10.1074\/jbc.M405924200","volume":"279","author":"JB Demoulin","year":"2004","unstructured":"Demoulin JB, Ericsson J, Kallin A, Rorsman C, R\u00f6nnstrand L, Heldin CH. Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem. 2004;279:35392.","journal-title":"J Biol Chem"},{"key":"2385_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","volume":"8","author":"T Porstmann","year":"2008","unstructured":"Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8:224.","journal-title":"Cell Metab"},{"key":"2385_CR21","first-page":"8167","volume":"63","author":"M Sch\u00fcle","year":"2021","unstructured":"Sch\u00fcle M, Butto T, Dewi S, Schlichtholz L, Strand S, Gerber S, et al. Mtor driven gene transcription is required for cholesterol production in neurons of the developing cerebral cortex. Int J Mol Sci. 2021;63:8167.","journal-title":"Int J Mol Sci"},{"key":"2385_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.abb.2007.06.029","volume":"465","author":"KG Sidiropoulos","year":"2007","unstructured":"Sidiropoulos KG, Meshkani R, Avramoglu-Kohen R, Adeli K. Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase\/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation. Arch Biochem Biophys. 2007;465:380.","journal-title":"Arch Biochem Biophys"},{"key":"2385_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.tem.2013.04.001","volume":"24","author":"ME Haas","year":"2013","unstructured":"Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab. 2013;24:391.","journal-title":"Trends Endocrinol Metab"},{"key":"2385_CR24","doi-asserted-by":"crossref","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA - J Am Med Assoc. 2012.","DOI":"10.1016\/j.yend.2012.05.028"},{"issue":"2","key":"2385_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabres.2015.09.014","volume":"110","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B, Cariou B. MTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015;110(2):101\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"2385_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell"},{"issue":"3","key":"2385_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.pharep.2016.01.005","volume":"68","author":"K Sadowski","year":"2016","unstructured":"Sadowski K, Kotulska K, J\u00f3\u017awiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Reports. 2016;68(3):536\u201342.","journal-title":"Pharmacol Reports"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02385-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:07:56Z","timestamp":1657278476000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02385-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02385-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave informed consent for the Dutch TSC registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}